Delving into the Latest Updates on HeXell-2020 with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Allogenic umbilical cord mesenchymal stem cells(HeXun Biosciences), HeXell-2020

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesOther Diseases

Active Indication

Angina PectorisFrailty Syndrome

Inactive Indication-

Originator Organization

HeXun Biosciences Co., Ltd.

Active Organization

HeXun Biosciences Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This is a phase I study to investigate the safety, and Tolerability of HeXell-2020 in Elderly Subjects with Mild to Moderate Frailty Syndrome.
HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.

Start Date31 Jan 2026

Sponsor / Collaborator

HeXun Biosciences Co., Ltd.

NCT07137104

/ Not yet recruitingPhase 1/2

A Phase I/IIa Study to Investigate the Safety, Tolerability, and Preliminary Effectiveness of HeXell-2020 in Patients With Stable Coronary Artery Disease (CAD)

This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.

Start Date01 Dec 2025

Sponsor / Collaborator

HeXun Biosciences Co., Ltd.

100 Clinical Results associated with HeXell-2020

Login to view more data

100 Translational Medicine associated with HeXell-2020

Login to view more data

100 Patents (Medical) associated with HeXell-2020

Login to view more data

100 Deals associated with HeXell-2020

Login to view more data